Most patients with small cell lung cancer (SCLC) have disseminated disease at time of diagnosis. Although SCLC is initially very sensitive to chemotherapy, the responses are of short duration and relapse of the disease occurs rapidly in 90-95% of the cases. For limited disease the 5-year survival rate is only about 5-10% (Albain et al., 1991) , and the 2-year survival rate for extensive disease is less than 6% (Albain et al., 1991) .
To improve the situation, autologous bone marrow transplantation (ABMT) combined with high dose chemotherapy has been tried (Humblet et al., 1987; Symann et al., 1989; Souhami et al., 1989; Williams et al., 1989; Marangolo et al., 1989; Nomura et al., 1990; Lazarus et al., 1990; Gomm et al., 1991) . This treatment has increased the number of patients with complete remissions (Humblet et al., 1987; Souhami et al., 1989) and improved relapse free-survival (Humblet et al., 1987; Symann et al., 1989) , but, unfortunately, the long time survival rate has not increased significantly. One contributing factor may be infiltration of tumour cells in the transfused bone marrow. It has become increasingly clear that tumour cells are often present in the marrow of SCLC patients, even if cytomorphological and histomorphological analysis remains negative Berendsen et al., 1988; Canon et al., 1988; Trillet et al., 1989; Beiske et al., 1992) . In order to prevent giving tumour cells back to the patient, it is logical to purge the bone marrow for tumour cells before reinfusion. The usefulness of immunological, physical and chemical procedures have been examined for this purpose (Gordon et al., 1984; Mabry et al., 1985; Okabe et al., 1985; Benard et al., 1988; Combaret et al., 1988; Vredenburgh & Ball, 1990; Humblet et al., 1989; Meagher et al., 1989; Elias et al., 1990) .
In this study the purging efficacy of immunomagnetic beads used in combination with four different monoclonal antibodies (MAbs), previously selected from a panel of 17 MAbs (Myklebust et al., 1991) 
Cell line
The H-146 human SCLC cell line (Carney et al., 1985) , kindly provided by Dr Adi F. Gazdar, National Cancer Institute, Bethesda, MD, USA, was used in the experiments. The cells were grown as suspension cultures in RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 10% foetal calf serum (FCS).
Monoclonal antibodies MOC-1 (Leij et al., 1985) and MOC-31 (Leij et al., 1986) antibodies were gifts from Dr L. de Leij, Groningen, The Netherlands. MOC-1 (IgGI) binds to the neural cell adhesion molecule (CD56/NCAM) (Moolenaar et al., 1990) , and MOC-31 (IgG2a) to an epithelial antigen (cluster 2). NrLulO (also denoted TFS-2), an IgG2b antibody recognising a 39 kDa antigen (Okabe et al., 1984) (Ripamonti et al., 1987 (Courtenay & Mills, 1978) , as previously described for malignant B cells . Briefly, soft agar cultures were set up in triplicates in 10 ml tubes by adding 0.2 ml August rat blood diluted 1 to 8, 0.2 ml of appropriately diluted bone marrow/tumour cell suspensions, and 0.6 ml of 0.5% agar (Difco Laboratories, Detroit, Michigan, USA). The tubes were incubated at 37°C in 5% 02, 5% CO2, and 90% N2, and after 21 days of incubation colonies of more than 50 cells were counted using a Zeiss stereo microscope.
The clonogenic progenitor cells remaining in the bone marrow after immunobead separation were assessed in a modified version of the method described by Burgess et al. (1977) . Mononuclear BM cells were suspended at a concentration of 2 x I05 cells ml-' in MCCOY'S 5A medium (Gibco) containing 0.3% agar, 15% FCS, 20 ng of GM-CSF (kindly provided by Schering Plough, NJ, USA) and antibiotics. Triplicate 1 ml aliquots were cultured in 35 mm plastic dishes at 37'C in 5% 02, 5% CO2, and 90% N2. After 14 days of incubation colonies of more than 40 cells were counted.
In the GEMM assay (Messner et al., 1982) , 2 x 105 mononuclear cells were suspended in 1 ml Iscove's modified Dulbecco's medium (Gibco) containing 0.8% methylcellulose, 10% FCS, 10% leucocyte conditioned medium, 30% human plasma, 5 x 10-5 M 2-mercaptoethanol and 1 unit of erythropoietin (Cilag Ltd., Schaffhausen, Switzerland). Triplicate 1 ml aliquots were cultured and colonies counted as for the GM assay.
Results
Cloning efficiency of SCLC cells When different numbers of H-146 cells were seeded out in soft agar the number of colonies formed was proportional to the number of cells plated (Figure 1 ). This relationship was close to linear down to ten cells plated per tube, and the plating efficiency calculated from the slope of the curve was approximately 40% in three independent experiments. Similar curves were established in each model experiment, and the curves were used to calculate the tumour cell depletion obtained by the treatment, taking the plating efficiency in each experiment into account. Efficacy of the treatment is given as the logarithm of the number of tumour cells removed.
Tumour cell removal
Efficacy of immunobeads used with single and combinations of two MAbs Of the individual MAbs, MOC-1 and NrLulO were the most effective in the immunomagnetic procedure, resulting in 3.7 log and 3.6 log tumour cell removal, respectively (Table I ). The corresponding value for MLuCl was 2.6 log, compared to 2.1 log for MOC-3 1. When the procedure was performed twice, a significant increase in efficacy was obtained for MOC-1 (4.4 log depletion) and for MLuCl (4.2 log depletion), whereas the values with the other two MAbs increased only slightly (Table I) .
Since it is known that tumour-associated antigens (Myklebust et al., 1991) . Also, the usefulness of the same antibodies for detecting bone marrow metastases in small cell lung cancer patients has recently been demonstrated . We have found that the NrLulO and MOC-31 antibodies bind to the same antigen, but to different epitopes (unpublished data). However, they differ in their ability to Treatment and calculations as in Table I . detect contaminating SCLC cells in fresh bone marrow aspirates , and as suggested by the present results, both antibodies should be included in a cocktail recommended for clinical use, together with MOC-1 and MLuCl that recognise distinct antigens (Moolenaar et al., 1990; Ripamonti et al., 1987) . To limit the need for fresh human bone marrow, the removal experiments with individual and combinations of two MAbs were performed on a suspension of H-146 cells only, as previous experience has shown that such experiments closely predict results obtained when tumour cells are mixed with normal bone marrow cells. In accordance with this, the present procedure proved to be equally effective when H-146 tumour cells were mixed with bone marrow cells at a ratio of 1:10. Thus, the optimal combinations of four MAbs resulted in a mean log tumour cell removal of 5.6 in the absence, and > 6.0 in the presence of bone marrow cells. In experiments with MOC-31 antibody no difference in log tumour cell removal was found between 1:10 and 1:100 mixes of SCLC and marrow cells (not shown). However, limited access to human bone marrow and the high efficacy of the purging method prevented further testing at a low tumour to bone marrow cell ratio. The validity of calculating log tumour cell removal is dependent on a close to linear relationship between the number of tumour cells plated and the number of soft agar colonies formed. This requirement was met with the H-146 cell line, which showed a high and reproducible plating efficiency in the clonogenic assay.
Several reports have described methods to eliminate SCLC cells from bone marrow (Gordon et al., 1984; Mabry et al., 1985; Okabe et al., 1985; Benard et al., 1988; Vredenburgh & Ball, 1990; Humblet et al., 1989; Meagher et al., 1989; Elias et al., 1990) . Vredenburgh & Ball (1990) obtained 4-5 log separation using immunomagnetic beads and three different antibodies, administered at a relatively high concentration, whereas the results of Elias et al. (1990) were less satisfactory (2.4-2.6 log). In both cases, two types of immunobeads had to be used because their tumour-associated primary antibodies were of both IgG and IgM isotypes. The results reported for other depletion procedures show varying degrees of efficacy and toxicity to normal bone marrow cells (Gordon et al., 1984; Mabry et al., 1985; Okabe et al., 1985; Benard et al., 1988; Meagher et al., 1989) , the best results (4-5 log depletion) obtained by Humblet et al. (1989) . The latter investigators combined immunological and pharmacological methods, and their regime was relatively toxic to bone marrow progenitor cells.
Altogether, the results in the present work were better than any of those previously reported, probably reflecting both the efficacy of immunomagnetic procedures (Kiesel et al., 1987; Kvalheim et al., 1988) and the properties of the antibodies used. In agreement with the experience of Vredenburgh & Ball (1990) , the best results were obtained with two purging cycles at a 50:1 ratio of beads to tumour cells. The procedure had only minor effects on cell survival in the bone marrow progenitor cell assays. Some bone marrow specimens used for these studies were obtained from patients with other types of malignancies but without bone marrow involvement. In a few of these cases, the proliferative capacity of the progenitor cells was relatively low. This did not influence the results, except that with MLuCl used alone an unpredictable variation in the number of surviving CFU-GMs was observed in some experiments.
High dose chemotherapy followed by ABMT in SCLC patients has been used by several investigators (Humblet et al., 1987; Symann et al., 1989; Souhami et al., 1989; Williams et al., 1989; Marangolo et al., 1989; Nomura et al., 1990; Lazarus et al., 1990; Gomm et al., 1991) Berendsen et al., 1988; Canon et al., 1988; Trillet et al., 1989; Beiske et al., 1992) . It should also be noted that the detection of tumour cells in bone marrow is based on studies of small volume aspirates, whereas about 11 of bone marrow is harvested for ABMT. Thus, the risk of tumour cell contamination of the transfused marrow may be higher than indicated by studying bone marrow aspirates.
One argument against ABMT in SCLC has been that several patients have relapsed locally in the lungs. It cannot be excluded, however, that these relapses are associated with i.v. transfusion of contaminated bone marrow cells. The reinfused cells will meet the first capillary bed in the lungs, and it is well known that interaction between tumour cells and host tissues favours tumour growth in orthotopic sites, in this case represented by the lungs. Furthermore, the effect of tumour cell trapping in the lungs is also exemplified by the finding of Glorieux et al. (1986) that a patient with neuroblastoma and another with Burkitts lymphoma developed diffuse carcinomatosis in the lungs after ABMT.
In cancer types where patients undergoing ABMT are at risk for having contaminating tumour cells in the bone marrow, it seems logical that the marrow should be purged before transfusion. Although the value of tumour cell purging has not been definitely proven, recent evidence indicates that effective removal of lymphoma cells from the marrow has a significant effect on the clinical outcome (Gribben et al., 1991) . We have previously developed highly effective immunomagnetic methods which are currently in routine clinical use in patients with B and T-cell malignancies (Kvalheim et al., 1988; Wang et al., 1992 ). The similar method described here for purging SCLC has been shown to be equally efficacious in tumour cell depletion from bone marrow, and the method is recommended for use in conjunction with ABMT in selected groups of SCLC patients.
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